Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Carotid Decision Making

12. listopadu 2026 aktualizováno: Jesse.A.Columbo, Dartmouth-Hitchcock Medical Center

Improving Shared Decision Making for Older Patients With Carotid Artery Stenosis

Carotid artery stenosis is a common cause of ischemic stroke in the U.S. and disproportionately affects older adults. Patients with carotid artery stenosis face a complex set of decisions when choosing a treatment strategy. Patients must choose among surveillance with medical therapy alone, versus medical therapy plus one of three different procedures. Each treatment option has different levels of evidence to support it, some of which are decades old. Each procedural option has different expected periprocedural courses, different recoveries, and different cardiovascular risks. This challenging decision is amplified among older adults, where decisional values are often different from younger patients traditionally studied in randomized or observational studies. A decision aid could assist patients and providers who are navigating this decision, but no decision aid currently exists that includes all the contemporary carotid artery stenosis treatment options. In addition, as of October 2023, participation in a shared decision-making conversation is a Medicare-mandated component of carotid stenosis care, with reimbursement for procedures predicated on the documentation of the conversation with the patient.

The objective of this project is to conduct a single arm open label trial to test the feasibility of using a paper-based decision aid for patients considering carotid revascularization. The investigators will conduct a feasibility trial using the decision aid on older adults who are considering carotid revascularization. The investigators will recruit 50 participants aged 65 or older from the vascular surgery clinic and administer the decision aid. The investigators will purposively sample at least 10 participants that are age 80 or older. Primary outcomes will center on feasibility, and secondary outcomes will center on decisional conflict and regret.

Přehled studie

Postavení

Zatím nenabíráme

Intervence / Léčba

Detailní popis

The primary outcomes of this single arm open label feasibility trial are focused on feasibility, and the secondary outcomes will provide data to inform a subsequent R01 study design.

Exposure: The decision aid

Setting: The investigators will sample newly referred and longitudinally treated patients from the Dartmouth Health Vascular Clinic who are being treated for carotid artery stenosis and who are considering carotid revascularization.

Sampling strategy: The investigators will enroll 50 patient-participants. The investigators will review the clinic schedules of the 18 providers each day in clinic and screen them for patients being seen for carotid artery stenosis. The investigators will then discuss with the providers in clinic that day whether any of the patients they are seeing may be considered for carotid revascularization and whether that respective patient would be appropriate for and have the capacity to utilize a decision aid. The investigators will purposively sample a minimum of 10 participants who are aged 80 and older to ensure adequate representation of this age group. Patients with carotid stenosis routinely have a high burden of comorbidities including hypertension, diabetes, coronary disease, kidney disease, and smoking. Patients treated in the Dartmouth Vascular Clinic are representative of this population and will allow us to sample a cohort with multiple comorbidities. Patients meeting the inclusion and exclusion criteria and felt to be appropriate for a decision aid per their treating provider will be approached in clinic to discuss the study.

Statistical analysis:

Outcome 1: The investigators will measure the mean and standard deviation of the time of the clinic visit. The investigators will calculate the visit time from the time of patient check in until the completion of the clinic visit, as assessed by a direct observer. The investigators will compare this to baseline time measurements recorded in the electronic health record for a random sample of 50 carotid stenosis patients meeting the same inclusion / exclusion criteria in the past 3 months.

Outcome 2: The investigators will conduct semi-structured interviews with 10 patients to follow up on the findings from the surveys above. These will be semi-structured interviews that are designed to assess whether the tradeoffs for each decision aid option were understood, and whether they felt that the decision aid helped them reach their choice. The interviews will be recorded and transcribed. The constant comparative method will be used to identify codes inductively. Two independent coders will analyze the data, and then codes will be discussed and data organized. Areas of disagreement will be resolved by consensus, or, if consensus is not possible, by a third independent reviewer. The investigators will organize the codes into key domains through data reduction and interpretation, paying particular attention to the frequency of specific ideas / codes mentioned by participants, and how many participants mentioned them.

The investigators will administer a similar survey to their treating providers within 1 week of the clinic visit. The results of the Likert surveys will be converted to a 5-point scale and the mean and median response will be computed with 95% confidence intervals. The investigators will additionally conduct semi-structured interviews with treating providers to determine feasibility of decision aid use in routine practice.

Secondary outcomes: The investigators will administer a validated decisional conflict scale and decisional regret scale before and after administration of the decision aid. The investigators will use the low literacy version to account for the high prevalence of low literacy in older adults. The investigators will analyze the results according to the validated methods for that survey and compare the before and after results. The investigators will additionally measure the actual treatment decision made by the patient and report this unadjusted. The investigators will finally measure knowledge-based questions that will be administered before and after patients are given the decision aid.

Sample size considerations: For outcome 1, given a sample size of 50 normally distributed outcomes, this will result in sample size with 95% confidence intervals with half widths of 0.32 standard deviation of the matched visit estimates of added time for increasing to 0.34, and 0.36 with 10% and 20% missing data. Similar results hold for the Likert survey in Outcome 3.

Potential pitfalls and alternative strategies: It is possible that it may not be known whether a patient would benefit from a decision aid until the patient receives an imaging study demonstrating the severity of the patient's carotid disease, which may occur just before the patient's clinic visit. Therefore, for patients who are scheduled for a clinic visit but do not have an imaging study, the investigators will ask the vascular laboratory (where the studies are conducted) to notify study personnel once the imaging study is completed.

Typ studie

Intervenční

Zápis (Odhadovaný)

50

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • New Hampshire
      • Lebanon, New Hampshire, Spojené státy, 03766
        • Dartmouth Hitchcock Medical Center

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

65 let a starší (Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Patients seen in the outpatient clinic who are considering carotid revascularization versus medical therapy or who were admitted to the hospital and are considering elective carotid revascularization.

Exclusion Criteria:

  • Patients who are considering urgent revascularization, those unable to provide informed consent using the Short Portable Mental Status Questionnaire or those unable to participate in follow-up interview or survey scales due to cognitive reasons.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Podpůrná péče
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Decision aid feasibility

Single arm pilot feasibility study of using a decision aid for patients with asymptomatic carotid artery stenosis considering revascularization

The decision aid is paper-based and includes pie charts of perioperative risks and incorporates patient values and preferences about autonomy of decision making.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Time to administer the decision aid
Časové okno: Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)

Defined as time from clinic check-in until completion of the visit

Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)
Understanding of the decision aid
Časové okno: Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)

Measured by a knowledge survey

Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Decisional conflict
Časové okno: Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)

Measured using the validated decisional conflict scale

Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)
Decisional regret
Časové okno: Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)

Measured using the validated decisional regret scale

Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)
Actual treatment decision made
Časové okno: Assessed for up to 8 weeks

What treatment the patient actually decided on

Assessed for up to 8 weeks

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

15. listopadu 2026

Primární dokončení (Odhadovaný)

15. května 2028

Dokončení studie (Odhadovaný)

15. května 2028

Termíny zápisu do studia

První předloženo

2. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

12. listopadu 2026

První zveřejněno (Aktuální)

17. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

17. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

12. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Popis plánu IPD

Will not share individual patient data due to confidentiality.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit